BR112012016549A2 - piperazinas como agentes antimalariais - Google Patents

piperazinas como agentes antimalariais

Info

Publication number
BR112012016549A2
BR112012016549A2 BR112012016549A BR112012016549A BR112012016549A2 BR 112012016549 A2 BR112012016549 A2 BR 112012016549A2 BR 112012016549 A BR112012016549 A BR 112012016549A BR 112012016549 A BR112012016549 A BR 112012016549A BR 112012016549 A2 BR112012016549 A2 BR 112012016549A2
Authority
BR
Brazil
Prior art keywords
piperazines
malarial agents
pharmaceutical compositions
relates
malarial
Prior art date
Application number
BR112012016549A
Other languages
English (en)
Other versions
BR112012016549A8 (pt
Inventor
Bibia Heidmann
Christoph Boss
Hamed Aissaoui
Olivier Corminboeuf
Romain Siegrist
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112012016549A2 publication Critical patent/BR112012016549A2/pt
Publication of BR112012016549A8 publication Critical patent/BR112012016549A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

piperazinas como agentes antimalariais. a invenção refere-se aos derivados de piperazina de fórmula i e a sua utilização como princípios ativos na preparação de composições farmacêuticas. a invenção também diz respeito aos aspectos relacionados incluindo composições farmacêuticas contendo um ou mais desses compostos e seu uso como medicamentos para o tratamento ou prevenção de infecções por protozoários, tal como, especialmente, malária.
BR112012016549A 2010-01-05 2011-01-04 Piperazinas como agentes antimalariais BR112012016549A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2010050022 2010-01-05
IB2010052045 2010-05-10
PCT/IB2011/050009 WO2011083413A1 (en) 2010-01-05 2011-01-04 Piperazines as antimalarial agents

Publications (2)

Publication Number Publication Date
BR112012016549A2 true BR112012016549A2 (pt) 2016-04-19
BR112012016549A8 BR112012016549A8 (pt) 2017-12-26

Family

ID=43706300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016549A BR112012016549A8 (pt) 2010-01-05 2011-01-04 Piperazinas como agentes antimalariais

Country Status (27)

Country Link
EP (1) EP2521715B1 (pt)
JP (1) JP5165166B1 (pt)
KR (1) KR101455484B1 (pt)
CN (1) CN102666488B (pt)
AR (1) AR079831A1 (pt)
AU (1) AU2011204436B2 (pt)
BR (1) BR112012016549A8 (pt)
CA (1) CA2783882C (pt)
CL (1) CL2012001641A1 (pt)
CY (1) CY1115600T1 (pt)
DK (1) DK2521715T3 (pt)
ES (1) ES2523739T3 (pt)
HK (1) HK1178529A1 (pt)
HR (1) HRP20140890T1 (pt)
IL (1) IL220698A (pt)
MA (1) MA33979B1 (pt)
MX (1) MX2012007172A (pt)
MY (1) MY160904A (pt)
NZ (1) NZ601607A (pt)
PL (1) PL2521715T3 (pt)
PT (1) PT2521715E (pt)
RU (1) RU2555706C2 (pt)
SG (1) SG181462A1 (pt)
SI (1) SI2521715T1 (pt)
TW (1) TWI402267B (pt)
WO (1) WO2011083413A1 (pt)
ZA (1) ZA201205879B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018069A1 (en) 2011-08-04 2013-02-07 Actelion Pharmaceuticals Ltd Combination of antimalarial agents
WO2014072903A1 (en) * 2012-11-06 2014-05-15 Actelion Pharmaceuticals Ltd Novel aminomethyl-phenol derivatives as antimalarial agents
BR112015023560A8 (pt) 2013-03-15 2017-12-26 Actelion Pharmaceuticals Ltd Novos derivados de acrilamida como agentes antimaláricos
CN114829351A (zh) * 2020-01-21 2022-07-29 卫材R&D管理有限公司 含有杂环化合物的新颖抗疟剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
DE10008522A1 (de) * 2000-02-24 2001-09-06 Hassan Jomaa Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen
EA006079B1 (ru) * 2000-03-31 2005-08-25 Пфайзер Продактс Инк. Новые пиперазиновые производные
AR057836A1 (es) 2005-10-21 2007-12-19 Actelion Pharmaceuticals Ltd Piperizinas como agentes contra la malaria
CN101544630B (zh) * 2009-05-13 2013-03-13 中国科学院广州生物医药与健康研究院 羟基化茚地那韦的制备方法

Also Published As

Publication number Publication date
KR20120111740A (ko) 2012-10-10
WO2011083413A1 (en) 2011-07-14
EP2521715A1 (en) 2012-11-14
HK1178529A1 (en) 2013-09-13
CN102666488A (zh) 2012-09-12
MY160904A (en) 2017-03-31
BR112012016549A8 (pt) 2017-12-26
RU2555706C2 (ru) 2015-07-10
TWI402267B (zh) 2013-07-21
MX2012007172A (es) 2012-07-03
KR101455484B1 (ko) 2014-10-27
CA2783882A1 (en) 2011-07-14
AU2011204436A1 (en) 2012-08-23
PL2521715T3 (pl) 2014-11-28
IL220698A (en) 2015-09-24
ZA201205879B (en) 2015-04-29
CN102666488B (zh) 2015-04-22
ES2523739T3 (es) 2014-12-01
CL2012001641A1 (es) 2012-12-07
EP2521715B1 (en) 2014-06-25
TW201139416A (en) 2011-11-16
SG181462A1 (en) 2012-07-30
CA2783882C (en) 2017-11-28
NZ601607A (en) 2014-06-27
AU2011204436B2 (en) 2016-05-19
MA33979B1 (fr) 2013-02-01
CY1115600T1 (el) 2017-01-04
HRP20140890T1 (hr) 2014-11-07
RU2012133265A (ru) 2014-02-20
PT2521715E (pt) 2014-09-02
JP5165166B1 (ja) 2013-03-21
JP2013516453A (ja) 2013-05-13
SI2521715T1 (sl) 2014-10-30
AR079831A1 (es) 2012-02-22
DK2521715T3 (da) 2014-08-11

Similar Documents

Publication Publication Date Title
AR117001A2 (es) Formulación de premezcla de dexmedetomidina
TW200800931A (en) Novel piperazines as antimalarial agents
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
EA201401351A1 (ru) Производные бензимидазол-пролина
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BR112015017331A2 (pt) compostos químicos
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112012017705A2 (pt) derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112017001160A2 (pt) [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas
BR112012016549A2 (pt) piperazinas como agentes antimalariais
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201490573A1 (ru) Соединение бензотиазолона
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]